nodes	percent_of_prediction	percent_of_DWPC	metapath
Vilazodone—Irritability—Valrubicin—urinary bladder cancer	0.0207	0.0304	CcSEcCtD
Vilazodone—Pollakiuria—Valrubicin—urinary bladder cancer	0.0173	0.0254	CcSEcCtD
Vilazodone—Flatulence—Valrubicin—urinary bladder cancer	0.0128	0.0189	CcSEcCtD
Vilazodone—Cataract—Thiotepa—urinary bladder cancer	0.0109	0.0159	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Valrubicin—urinary bladder cancer	0.00969	0.0142	CcSEcCtD
Vilazodone—Feeling abnormal—Valrubicin—urinary bladder cancer	0.00877	0.0129	CcSEcCtD
Vilazodone—Vision blurred—Mitomycin—urinary bladder cancer	0.00846	0.0124	CcSEcCtD
Vilazodone—Asthenia—Valrubicin—urinary bladder cancer	0.00763	0.0112	CcSEcCtD
Vilazodone—Diarrhoea—Valrubicin—urinary bladder cancer	0.00728	0.0107	CcSEcCtD
Vilazodone—Dizziness—Valrubicin—urinary bladder cancer	0.00703	0.0103	CcSEcCtD
Vilazodone—Vomiting—Valrubicin—urinary bladder cancer	0.00676	0.00994	CcSEcCtD
Vilazodone—Somnolence—Mitomycin—urinary bladder cancer	0.00652	0.00958	CcSEcCtD
Vilazodone—Decreased appetite—Mitomycin—urinary bladder cancer	0.00637	0.00936	CcSEcCtD
Vilazodone—Nausea—Valrubicin—urinary bladder cancer	0.00632	0.00929	CcSEcCtD
Vilazodone—Fatigue—Mitomycin—urinary bladder cancer	0.00632	0.00929	CcSEcCtD
Vilazodone—Feeling abnormal—Mitomycin—urinary bladder cancer	0.00604	0.00888	CcSEcCtD
Vilazodone—Irritability—Fluorouracil—urinary bladder cancer	0.00592	0.0087	CcSEcCtD
Vilazodone—Hyponatraemia—Cisplatin—urinary bladder cancer	0.0059	0.00868	CcSEcCtD
Vilazodone—Irritability—Cisplatin—urinary bladder cancer	0.00561	0.00825	CcSEcCtD
Vilazodone—Breast disorder—Cisplatin—urinary bladder cancer	0.00531	0.00781	CcSEcCtD
Vilazodone—Asthenia—Mitomycin—urinary bladder cancer	0.00526	0.00773	CcSEcCtD
Vilazodone—Hallucination—Thiotepa—urinary bladder cancer	0.00516	0.00759	CcSEcCtD
Vilazodone—Connective tissue disorder—Thiotepa—urinary bladder cancer	0.0051	0.00749	CcSEcCtD
Vilazodone—Diarrhoea—Mitomycin—urinary bladder cancer	0.00501	0.00737	CcSEcCtD
Vilazodone—Eye disorder—Thiotepa—urinary bladder cancer	0.00485	0.00713	CcSEcCtD
Vilazodone—Dizziness—Mitomycin—urinary bladder cancer	0.00485	0.00712	CcSEcCtD
Vilazodone—Cardiac disorder—Thiotepa—urinary bladder cancer	0.00481	0.00708	CcSEcCtD
Vilazodone—Vomiting—Mitomycin—urinary bladder cancer	0.00466	0.00685	CcSEcCtD
Vilazodone—Ventricular extrasystoles—Epirubicin—urinary bladder cancer	0.00461	0.00677	CcSEcCtD
Vilazodone—CYP2C18—Biological oxidations—UGT2B7—urinary bladder cancer	0.00458	0.0143	CbGpPWpGaD
Vilazodone—Mental disorder—Thiotepa—urinary bladder cancer	0.00454	0.00668	CcSEcCtD
Vilazodone—Malnutrition—Thiotepa—urinary bladder cancer	0.00452	0.00664	CcSEcCtD
Vilazodone—CYP2C18—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00451	0.0141	CbGpPWpGaD
Vilazodone—CYP3A4—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00446	0.014	CbGpPWpGaD
Vilazodone—Nervousness—Thiotepa—urinary bladder cancer	0.00439	0.00645	CcSEcCtD
Vilazodone—Nausea—Mitomycin—urinary bladder cancer	0.00435	0.0064	CcSEcCtD
Vilazodone—Connective tissue disorder—Gemcitabine—urinary bladder cancer	0.00429	0.0063	CcSEcCtD
Vilazodone—Ventricular extrasystoles—Doxorubicin—urinary bladder cancer	0.00426	0.00626	CcSEcCtD
Vilazodone—Vision blurred—Thiotepa—urinary bladder cancer	0.00426	0.00626	CcSEcCtD
Vilazodone—Agitation—Thiotepa—urinary bladder cancer	0.00415	0.0061	CcSEcCtD
Vilazodone—CYP2C18—Biological oxidations—CYP4B1—urinary bladder cancer	0.00412	0.0129	CbGpPWpGaD
Vilazodone—Abnormal dreams—Epirubicin—urinary bladder cancer	0.00411	0.00604	CcSEcCtD
Vilazodone—CYP2C18—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00406	0.0127	CbGpPWpGaD
Vilazodone—Cardiac disorder—Gemcitabine—urinary bladder cancer	0.00405	0.00595	CcSEcCtD
Vilazodone—Connective tissue disorder—Cisplatin—urinary bladder cancer	0.004	0.00587	CcSEcCtD
Vilazodone—CYP3A4—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.00392	0.0123	CbGpPWpGaD
Vilazodone—Convulsion—Thiotepa—urinary bladder cancer	0.00391	0.00575	CcSEcCtD
Vilazodone—Arthralgia—Thiotepa—urinary bladder cancer	0.00384	0.00565	CcSEcCtD
Vilazodone—Dry eye—Epirubicin—urinary bladder cancer	0.00384	0.00565	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.00382	0.00561	CcSEcCtD
Vilazodone—Abnormal dreams—Doxorubicin—urinary bladder cancer	0.0038	0.00559	CcSEcCtD
Vilazodone—Eye disorder—Cisplatin—urinary bladder cancer	0.0038	0.00559	CcSEcCtD
Vilazodone—Cardiac disorder—Cisplatin—urinary bladder cancer	0.00377	0.00555	CcSEcCtD
Vilazodone—Nervous system disorder—Thiotepa—urinary bladder cancer	0.00361	0.00531	CcSEcCtD
Vilazodone—SLC6A4—Circadian rythm related genes—KMT2A—urinary bladder cancer	0.0036	0.0113	CbGpPWpGaD
Vilazodone—Skin disorder—Thiotepa—urinary bladder cancer	0.00358	0.00526	CcSEcCtD
Vilazodone—Dry eye—Doxorubicin—urinary bladder cancer	0.00355	0.00522	CcSEcCtD
Vilazodone—Malnutrition—Cisplatin—urinary bladder cancer	0.00354	0.0052	CcSEcCtD
Vilazodone—Vision blurred—Fluorouracil—urinary bladder cancer	0.00352	0.00517	CcSEcCtD
Vilazodone—Flatulence—Cisplatin—urinary bladder cancer	0.00349	0.00513	CcSEcCtD
Vilazodone—Eye disorder—Etoposide—urinary bladder cancer	0.00348	0.00512	CcSEcCtD
Vilazodone—Cardiac disorder—Etoposide—urinary bladder cancer	0.00346	0.00508	CcSEcCtD
Vilazodone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.00337	0.0105	CbGpPWpGaD
Vilazodone—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.00336	0.00494	CcSEcCtD
Vilazodone—Vision blurred—Cisplatin—urinary bladder cancer	0.00334	0.0049	CcSEcCtD
Vilazodone—Tremor—Cisplatin—urinary bladder cancer	0.00332	0.00488	CcSEcCtD
Vilazodone—Paraesthesia—Thiotepa—urinary bladder cancer	0.00331	0.00486	CcSEcCtD
Vilazodone—Somnolence—Thiotepa—urinary bladder cancer	0.00328	0.00482	CcSEcCtD
Vilazodone—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00327	0.0102	CbGpPWpGaD
Vilazodone—Dyspepsia—Thiotepa—urinary bladder cancer	0.00324	0.00477	CcSEcCtD
Vilazodone—Convulsion—Fluorouracil—urinary bladder cancer	0.00324	0.00476	CcSEcCtD
Vilazodone—Arthralgia—Gemcitabine—urinary bladder cancer	0.00323	0.00475	CcSEcCtD
Vilazodone—CYP2D6—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00323	0.0101	CbGpPWpGaD
Vilazodone—Increased appetite—Epirubicin—urinary bladder cancer	0.00321	0.00472	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.00321	0.00472	CcSEcCtD
Vilazodone—Decreased appetite—Thiotepa—urinary bladder cancer	0.0032	0.00471	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.00318	0.00468	CcSEcCtD
Vilazodone—Fatigue—Thiotepa—urinary bladder cancer	0.00318	0.00467	CcSEcCtD
Vilazodone—Dysgeusia—Etoposide—urinary bladder cancer	0.00318	0.00467	CcSEcCtD
Vilazodone—CYP2C18—FOXA1 transcription factor network—ESR1—urinary bladder cancer	0.00317	0.0099	CbGpPWpGaD
Vilazodone—Irritability—Methotrexate—urinary bladder cancer	0.00308	0.00453	CcSEcCtD
Vilazodone—Convulsion—Cisplatin—urinary bladder cancer	0.00307	0.00451	CcSEcCtD
Vilazodone—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.00304	0.00447	CcSEcCtD
Vilazodone—Feeling abnormal—Thiotepa—urinary bladder cancer	0.00304	0.00446	CcSEcCtD
Vilazodone—Hyponatraemia—Epirubicin—urinary bladder cancer	0.00303	0.00446	CcSEcCtD
Vilazodone—Skin disorder—Gemcitabine—urinary bladder cancer	0.00301	0.00443	CcSEcCtD
Vilazodone—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.003	0.00441	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.00299	0.0044	CcSEcCtD
Vilazodone—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.00299	0.00439	CcSEcCtD
Vilazodone—Increased appetite—Doxorubicin—urinary bladder cancer	0.00297	0.00437	CcSEcCtD
Vilazodone—Migraine—Epirubicin—urinary bladder cancer	0.00297	0.00437	CcSEcCtD
Vilazodone—Breast disorder—Methotrexate—urinary bladder cancer	0.00292	0.00429	CcSEcCtD
Vilazodone—Nervous system disorder—Cisplatin—urinary bladder cancer	0.00283	0.00417	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.00282	0.00415	CcSEcCtD
Vilazodone—Convulsion—Etoposide—urinary bladder cancer	0.00281	0.00413	CcSEcCtD
Vilazodone—Skin disorder—Cisplatin—urinary bladder cancer	0.00281	0.00413	CcSEcCtD
Vilazodone—Hyponatraemia—Doxorubicin—urinary bladder cancer	0.0028	0.00412	CcSEcCtD
Vilazodone—Insomnia—Gemcitabine—urinary bladder cancer	0.0028	0.00412	CcSEcCtD
Vilazodone—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.00279	0.00411	CcSEcCtD
Vilazodone—Paraesthesia—Gemcitabine—urinary bladder cancer	0.00278	0.00409	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.00278	0.00408	CcSEcCtD
Vilazodone—CYP2C18—FOXA1 transcription factor network—CREBBP—urinary bladder cancer	0.00277	0.00868	CbGpPWpGaD
Vilazodone—Insomnia—Fluorouracil—urinary bladder cancer	0.00276	0.00405	CcSEcCtD
Vilazodone—Somnolence—Gemcitabine—urinary bladder cancer	0.00276	0.00405	CcSEcCtD
Vilazodone—Migraine—Doxorubicin—urinary bladder cancer	0.00275	0.00404	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.00274	0.00403	CcSEcCtD
Vilazodone—CYP2C18—Biological oxidations—NAT2—urinary bladder cancer	0.00274	0.00858	CbGpPWpGaD
Vilazodone—Paraesthesia—Fluorouracil—urinary bladder cancer	0.00274	0.00402	CcSEcCtD
Vilazodone—Breast disorder—Epirubicin—urinary bladder cancer	0.00273	0.00401	CcSEcCtD
Vilazodone—Somnolence—Fluorouracil—urinary bladder cancer	0.00271	0.00398	CcSEcCtD
Vilazodone—CYP2C18—Metapathway biotransformation—NAT2—urinary bladder cancer	0.0027	0.00846	CbGpPWpGaD
Vilazodone—Decreased appetite—Gemcitabine—urinary bladder cancer	0.0027	0.00396	CcSEcCtD
Vilazodone—Dyspepsia—Fluorouracil—urinary bladder cancer	0.00268	0.00394	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.00268	0.00393	CcSEcCtD
Vilazodone—Fatigue—Gemcitabine—urinary bladder cancer	0.00267	0.00393	CcSEcCtD
Vilazodone—CYP2D6—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00265	0.00829	CbGpPWpGaD
Vilazodone—Decreased appetite—Fluorouracil—urinary bladder cancer	0.00265	0.00389	CcSEcCtD
Vilazodone—Asthenia—Thiotepa—urinary bladder cancer	0.00264	0.00389	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.00263	0.00387	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.00263	0.00387	CcSEcCtD
Vilazodone—Paraesthesia—Cisplatin—urinary bladder cancer	0.00259	0.00381	CcSEcCtD
Vilazodone—Skin disorder—Etoposide—urinary bladder cancer	0.00257	0.00378	CcSEcCtD
Vilazodone—Erectile dysfunction—Methotrexate—urinary bladder cancer	0.00257	0.00377	CcSEcCtD
Vilazodone—Hyperhidrosis—Etoposide—urinary bladder cancer	0.00256	0.00376	CcSEcCtD
Vilazodone—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.00255	0.00375	CcSEcCtD
Vilazodone—Breast disorder—Doxorubicin—urinary bladder cancer	0.00252	0.00371	CcSEcCtD
Vilazodone—Diarrhoea—Thiotepa—urinary bladder cancer	0.00252	0.00371	CcSEcCtD
Vilazodone—Decreased appetite—Cisplatin—urinary bladder cancer	0.00251	0.00369	CcSEcCtD
Vilazodone—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.00251	0.00369	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.00249	0.00367	CcSEcCtD
Vilazodone—Dizziness—Thiotepa—urinary bladder cancer	0.00244	0.00358	CcSEcCtD
Vilazodone—Pollakiuria—Epirubicin—urinary bladder cancer	0.00241	0.00354	CcSEcCtD
Vilazodone—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	0.0024	0.00751	CbGpPWpGaD
Vilazodone—Feeling abnormal—Cisplatin—urinary bladder cancer	0.00238	0.0035	CcSEcCtD
Vilazodone—Paraesthesia—Etoposide—urinary bladder cancer	0.00238	0.00349	CcSEcCtD
Vilazodone—Somnolence—Etoposide—urinary bladder cancer	0.00235	0.00346	CcSEcCtD
Vilazodone—Vomiting—Thiotepa—urinary bladder cancer	0.00234	0.00344	CcSEcCtD
Vilazodone—Decreased appetite—Etoposide—urinary bladder cancer	0.0023	0.00338	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.00229	0.00336	CcSEcCtD
Vilazodone—Fatigue—Etoposide—urinary bladder cancer	0.00228	0.00335	CcSEcCtD
Vilazodone—Pollakiuria—Doxorubicin—urinary bladder cancer	0.00223	0.00328	CcSEcCtD
Vilazodone—Asthenia—Gemcitabine—urinary bladder cancer	0.00222	0.00327	CcSEcCtD
Vilazodone—DRD2—Circadian rythm related genes—KMT2A—urinary bladder cancer	0.0022	0.00688	CbGpPWpGaD
Vilazodone—CYP2C18—Biological oxidations—HPGDS—urinary bladder cancer	0.00219	0.00686	CbGpPWpGaD
Vilazodone—Nausea—Thiotepa—urinary bladder cancer	0.00219	0.00322	CcSEcCtD
Vilazodone—Feeling abnormal—Etoposide—urinary bladder cancer	0.00218	0.00321	CcSEcCtD
Vilazodone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00214	0.00669	CbGpPWpGaD
Vilazodone—CYP2C18—Biological oxidations—GSTT1—urinary bladder cancer	0.00213	0.00665	CbGpPWpGaD
Vilazodone—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00212	0.00312	CcSEcCtD
Vilazodone—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00211	0.0066	CbGpPWpGaD
Vilazodone—Eye disorder—Methotrexate—urinary bladder cancer	0.00209	0.00307	CcSEcCtD
Vilazodone—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00209	0.00307	CcSEcCtD
Vilazodone—Asthenia—Cisplatin—urinary bladder cancer	0.00207	0.00305	CcSEcCtD
Vilazodone—Cardiac disorder—Methotrexate—urinary bladder cancer	0.00207	0.00304	CcSEcCtD
Vilazodone—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.00205	0.00302	CcSEcCtD
Vilazodone—Dizziness—Fluorouracil—urinary bladder cancer	0.00202	0.00296	CcSEcCtD
Vilazodone—Diarrhoea—Cisplatin—urinary bladder cancer	0.00198	0.00291	CcSEcCtD
Vilazodone—Vomiting—Gemcitabine—urinary bladder cancer	0.00197	0.0029	CcSEcCtD
Vilazodone—Mental disorder—Methotrexate—urinary bladder cancer	0.00196	0.00287	CcSEcCtD
Vilazodone—Eye disorder—Epirubicin—urinary bladder cancer	0.00195	0.00287	CcSEcCtD
Vilazodone—Malnutrition—Methotrexate—urinary bladder cancer	0.00194	0.00286	CcSEcCtD
Vilazodone—Cardiac disorder—Epirubicin—urinary bladder cancer	0.00194	0.00285	CcSEcCtD
Vilazodone—Vomiting—Fluorouracil—urinary bladder cancer	0.00194	0.00285	CcSEcCtD
Vilazodone—SLC6A4—NRF2 pathway—NQO1—urinary bladder cancer	0.00193	0.00603	CbGpPWpGaD
Vilazodone—Dysgeusia—Methotrexate—urinary bladder cancer	0.0019	0.0028	CcSEcCtD
Vilazodone—Asthenia—Etoposide—urinary bladder cancer	0.0019	0.00279	CcSEcCtD
Vilazodone—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.0019	0.00279	CcSEcCtD
Vilazodone—SLC6A4—Monoamine Transport—TNF—urinary bladder cancer	0.00189	0.00593	CbGpPWpGaD
Vilazodone—CYP2C18—FOXA1 transcription factor network—EP300—urinary bladder cancer	0.00189	0.00591	CbGpPWpGaD
Vilazodone—Nausea—Gemcitabine—urinary bladder cancer	0.00184	0.00271	CcSEcCtD
Vilazodone—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	0.00184	0.00576	CbGpPWpGaD
Vilazodone—Vomiting—Cisplatin—urinary bladder cancer	0.00184	0.0027	CcSEcCtD
Vilazodone—Vision blurred—Methotrexate—urinary bladder cancer	0.00183	0.00269	CcSEcCtD
Vilazodone—Mental disorder—Epirubicin—urinary bladder cancer	0.00183	0.00269	CcSEcCtD
Vilazodone—Malnutrition—Epirubicin—urinary bladder cancer	0.00182	0.00267	CcSEcCtD
Vilazodone—SLC6A4—SIDS Susceptibility Pathways—ESR2—urinary bladder cancer	0.00182	0.00568	CbGpPWpGaD
Vilazodone—Diarrhoea—Etoposide—urinary bladder cancer	0.00181	0.00266	CcSEcCtD
Vilazodone—Nausea—Fluorouracil—urinary bladder cancer	0.00181	0.00266	CcSEcCtD
Vilazodone—Eye disorder—Doxorubicin—urinary bladder cancer	0.00181	0.00265	CcSEcCtD
Vilazodone—CYP2D6—Biological oxidations—GSTZ1—urinary bladder cancer	0.0018	0.00564	CbGpPWpGaD
Vilazodone—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.00179	0.00264	CcSEcCtD
Vilazodone—Flatulence—Epirubicin—urinary bladder cancer	0.00179	0.00263	CcSEcCtD
Vilazodone—Dysgeusia—Epirubicin—urinary bladder cancer	0.00178	0.00262	CcSEcCtD
Vilazodone—CYP2D6—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00178	0.00556	CbGpPWpGaD
Vilazodone—Nervousness—Epirubicin—urinary bladder cancer	0.00177	0.0026	CcSEcCtD
Vilazodone—Dizziness—Etoposide—urinary bladder cancer	0.00175	0.00257	CcSEcCtD
Vilazodone—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00173	0.00542	CbGpPWpGaD
Vilazodone—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.00173	0.0054	CbGpPWpGaD
Vilazodone—Nausea—Cisplatin—urinary bladder cancer	0.00172	0.00252	CcSEcCtD
Vilazodone—Vision blurred—Epirubicin—urinary bladder cancer	0.00171	0.00252	CcSEcCtD
Vilazodone—CYP2D6—Biological oxidations—GSTO2—urinary bladder cancer	0.00171	0.00535	CbGpPWpGaD
Vilazodone—CYP2D6—Biological oxidations—NAT1—urinary bladder cancer	0.00171	0.00535	CbGpPWpGaD
Vilazodone—Mental disorder—Doxorubicin—urinary bladder cancer	0.00169	0.00249	CcSEcCtD
Vilazodone—CYP2D6—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.00169	0.00528	CbGpPWpGaD
Vilazodone—Convulsion—Methotrexate—urinary bladder cancer	0.00168	0.00247	CcSEcCtD
Vilazodone—Vomiting—Etoposide—urinary bladder cancer	0.00168	0.00247	CcSEcCtD
Vilazodone—Malnutrition—Doxorubicin—urinary bladder cancer	0.00168	0.00247	CcSEcCtD
Vilazodone—Agitation—Epirubicin—urinary bladder cancer	0.00167	0.00246	CcSEcCtD
Vilazodone—Flatulence—Doxorubicin—urinary bladder cancer	0.00166	0.00244	CcSEcCtD
Vilazodone—Arthralgia—Methotrexate—urinary bladder cancer	0.00165	0.00243	CcSEcCtD
Vilazodone—Dysgeusia—Doxorubicin—urinary bladder cancer	0.00165	0.00242	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.00164	0.00241	CcSEcCtD
Vilazodone—Nervousness—Doxorubicin—urinary bladder cancer	0.00163	0.0024	CcSEcCtD
Vilazodone—SLC6A4—NRF2 pathway—GSTP1—urinary bladder cancer	0.00161	0.00503	CbGpPWpGaD
Vilazodone—Palpitations—Epirubicin—urinary bladder cancer	0.00161	0.00236	CcSEcCtD
Vilazodone—Vision blurred—Doxorubicin—urinary bladder cancer	0.00159	0.00233	CcSEcCtD
Vilazodone—Convulsion—Epirubicin—urinary bladder cancer	0.00158	0.00232	CcSEcCtD
Vilazodone—Nausea—Etoposide—urinary bladder cancer	0.00157	0.00231	CcSEcCtD
Vilazodone—CYP2D6—Biological oxidations—UGT2B7—urinary bladder cancer	0.00156	0.00489	CbGpPWpGaD
Vilazodone—Nervous system disorder—Methotrexate—urinary bladder cancer	0.00156	0.00229	CcSEcCtD
Vilazodone—Arthralgia—Epirubicin—urinary bladder cancer	0.00155	0.00228	CcSEcCtD
Vilazodone—Agitation—Doxorubicin—urinary bladder cancer	0.00155	0.00227	CcSEcCtD
Vilazodone—CYP2D6—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00154	0.00482	CbGpPWpGaD
Vilazodone—Skin disorder—Methotrexate—urinary bladder cancer	0.00154	0.00226	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.00154	0.00226	CcSEcCtD
Vilazodone—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.00153	0.00225	CcSEcCtD
Vilazodone—Dry mouth—Epirubicin—urinary bladder cancer	0.00151	0.00223	CcSEcCtD
Vilazodone—Palpitations—Doxorubicin—urinary bladder cancer	0.00149	0.00219	CcSEcCtD
Vilazodone—SLC6A4—NRF2 pathway—GSTM1—urinary bladder cancer	0.00148	0.00462	CbGpPWpGaD
Vilazodone—CYP2C18—Biological oxidations—GSTP1—urinary bladder cancer	0.00147	0.00461	CbGpPWpGaD
Vilazodone—Convulsion—Doxorubicin—urinary bladder cancer	0.00146	0.00214	CcSEcCtD
Vilazodone—Nervous system disorder—Epirubicin—urinary bladder cancer	0.00146	0.00214	CcSEcCtD
Vilazodone—CYP2C18—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.00145	0.00455	CbGpPWpGaD
Vilazodone—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.00144	0.00212	CcSEcCtD
Vilazodone—Skin disorder—Epirubicin—urinary bladder cancer	0.00144	0.00212	CcSEcCtD
Vilazodone—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.00143	0.00211	CcSEcCtD
Vilazodone—Insomnia—Methotrexate—urinary bladder cancer	0.00143	0.00211	CcSEcCtD
Vilazodone—Arthralgia—Doxorubicin—urinary bladder cancer	0.00143	0.00211	CcSEcCtD
Vilazodone—Paraesthesia—Methotrexate—urinary bladder cancer	0.00142	0.00209	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.00142	0.00209	CcSEcCtD
Vilazodone—Somnolence—Methotrexate—urinary bladder cancer	0.00141	0.00207	CcSEcCtD
Vilazodone—CYP2D6—Biological oxidations—CYP4B1—urinary bladder cancer	0.00141	0.0044	CbGpPWpGaD
Vilazodone—Dry mouth—Doxorubicin—urinary bladder cancer	0.0014	0.00206	CcSEcCtD
Vilazodone—Dyspepsia—Methotrexate—urinary bladder cancer	0.0014	0.00205	CcSEcCtD
Vilazodone—CYP2D6—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00139	0.00434	CbGpPWpGaD
Vilazodone—Decreased appetite—Methotrexate—urinary bladder cancer	0.00138	0.00203	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.00137	0.00201	CcSEcCtD
Vilazodone—Fatigue—Methotrexate—urinary bladder cancer	0.00137	0.00201	CcSEcCtD
Vilazodone—CYP2C18—Biological oxidations—GSTM1—urinary bladder cancer	0.00135	0.00424	CbGpPWpGaD
Vilazodone—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.00135	0.00199	CcSEcCtD
Vilazodone—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.00135	0.00198	CcSEcCtD
Vilazodone—Insomnia—Epirubicin—urinary bladder cancer	0.00134	0.00197	CcSEcCtD
Vilazodone—CYP2C18—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.00134	0.00418	CbGpPWpGaD
Vilazodone—Skin disorder—Doxorubicin—urinary bladder cancer	0.00133	0.00196	CcSEcCtD
Vilazodone—Paraesthesia—Epirubicin—urinary bladder cancer	0.00133	0.00196	CcSEcCtD
Vilazodone—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.00133	0.00195	CcSEcCtD
Vilazodone—Somnolence—Epirubicin—urinary bladder cancer	0.00132	0.00194	CcSEcCtD
Vilazodone—Feeling abnormal—Methotrexate—urinary bladder cancer	0.00131	0.00192	CcSEcCtD
Vilazodone—Dyspepsia—Epirubicin—urinary bladder cancer	0.00131	0.00192	CcSEcCtD
Vilazodone—Decreased appetite—Epirubicin—urinary bladder cancer	0.00129	0.0019	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.00128	0.00188	CcSEcCtD
Vilazodone—Fatigue—Epirubicin—urinary bladder cancer	0.00128	0.00188	CcSEcCtD
Vilazodone—HTR1A—SIDS Susceptibility Pathways—ESR2—urinary bladder cancer	0.00127	0.00396	CbGpPWpGaD
Vilazodone—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.00125	0.00184	CcSEcCtD
Vilazodone—Insomnia—Doxorubicin—urinary bladder cancer	0.00124	0.00183	CcSEcCtD
Vilazodone—Paraesthesia—Doxorubicin—urinary bladder cancer	0.00123	0.00181	CcSEcCtD
Vilazodone—Feeling abnormal—Epirubicin—urinary bladder cancer	0.00122	0.0018	CcSEcCtD
Vilazodone—Somnolence—Doxorubicin—urinary bladder cancer	0.00122	0.00179	CcSEcCtD
Vilazodone—Dyspepsia—Doxorubicin—urinary bladder cancer	0.00121	0.00178	CcSEcCtD
Vilazodone—Decreased appetite—Doxorubicin—urinary bladder cancer	0.00119	0.00175	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.00119	0.00174	CcSEcCtD
Vilazodone—Fatigue—Doxorubicin—urinary bladder cancer	0.00118	0.00174	CcSEcCtD
Vilazodone—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.00118	0.00369	CbGpPWpGaD
Vilazodone—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00116	0.00364	CbGpPWpGaD
Vilazodone—SLC6A4—Circadian rythm related genes—TYMS—urinary bladder cancer	0.00116	0.00362	CbGpPWpGaD
Vilazodone—SLC6A4—Circadian rythm related genes—NCOR1—urinary bladder cancer	0.00114	0.00358	CbGpPWpGaD
Vilazodone—Asthenia—Methotrexate—urinary bladder cancer	0.00114	0.00167	CcSEcCtD
Vilazodone—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.00113	0.00166	CcSEcCtD
Vilazodone—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.00112	0.0035	CbGpPWpGaD
Vilazodone—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.00112	0.0035	CbGpPWpGaD
Vilazodone—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.0011	0.00345	CbGpPWpGaD
Vilazodone—Diarrhoea—Methotrexate—urinary bladder cancer	0.00108	0.00159	CcSEcCtD
Vilazodone—Asthenia—Epirubicin—urinary bladder cancer	0.00106	0.00156	CcSEcCtD
Vilazodone—Dizziness—Methotrexate—urinary bladder cancer	0.00105	0.00154	CcSEcCtD
Vilazodone—SLC6A4—Circadian rythm related genes—FAS—urinary bladder cancer	0.00103	0.00321	CbGpPWpGaD
Vilazodone—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.00102	0.0032	CbGpPWpGaD
Vilazodone—Diarrhoea—Epirubicin—urinary bladder cancer	0.00102	0.00149	CcSEcCtD
Vilazodone—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00101	0.00315	CbGpPWpGaD
Vilazodone—Vomiting—Methotrexate—urinary bladder cancer	0.00101	0.00148	CcSEcCtD
Vilazodone—Asthenia—Doxorubicin—urinary bladder cancer	0.000985	0.00145	CcSEcCtD
Vilazodone—Dizziness—Epirubicin—urinary bladder cancer	0.000981	0.00144	CcSEcCtD
Vilazodone—SLC6A4—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	0.000965	0.00302	CbGpPWpGaD
Vilazodone—Vomiting—Epirubicin—urinary bladder cancer	0.000944	0.00139	CcSEcCtD
Vilazodone—Nausea—Methotrexate—urinary bladder cancer	0.000942	0.00138	CcSEcCtD
Vilazodone—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000939	0.00138	CcSEcCtD
Vilazodone—CYP2D6—Biological oxidations—NAT2—urinary bladder cancer	0.000937	0.00293	CbGpPWpGaD
Vilazodone—CYP2D6—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000924	0.00289	CbGpPWpGaD
Vilazodone—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.00092	0.00288	CbGpPWpGaD
Vilazodone—Dizziness—Doxorubicin—urinary bladder cancer	0.000908	0.00133	CcSEcCtD
Vilazodone—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000908	0.00284	CbGpPWpGaD
Vilazodone—SLC6A4—Circadian rythm related genes—CDK4—urinary bladder cancer	0.000903	0.00282	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—GSTZ1—urinary bladder cancer	0.000903	0.00282	CbGpPWpGaD
Vilazodone—Nausea—Epirubicin—urinary bladder cancer	0.000881	0.0013	CcSEcCtD
Vilazodone—Vomiting—Doxorubicin—urinary bladder cancer	0.000873	0.00128	CcSEcCtD
Vilazodone—CYP2C18—Metabolism—GSTO2—urinary bladder cancer	0.000856	0.00268	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—NAT1—urinary bladder cancer	0.000856	0.00268	CbGpPWpGaD
Vilazodone—SLC6A4—Circadian rythm related genes—PPARG—urinary bladder cancer	0.00082	0.00257	CbGpPWpGaD
Vilazodone—Nausea—Doxorubicin—urinary bladder cancer	0.000816	0.0012	CcSEcCtD
Vilazodone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000793	0.00248	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—UGT2B7—urinary bladder cancer	0.000783	0.00245	CbGpPWpGaD
Vilazodone—SLC6A4—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	0.000766	0.0024	CbGpPWpGaD
Vilazodone—CYP2D6—Biological oxidations—HPGDS—urinary bladder cancer	0.000749	0.00234	CbGpPWpGaD
Vilazodone—CYP2D6—Biological oxidations—GSTT1—urinary bladder cancer	0.000726	0.00227	CbGpPWpGaD
Vilazodone—DRD2—Circadian rythm related genes—TYMS—urinary bladder cancer	0.000708	0.00222	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—CYP4B1—urinary bladder cancer	0.000705	0.0022	CbGpPWpGaD
Vilazodone—DRD2—Circadian rythm related genes—NCOR1—urinary bladder cancer	0.0007	0.00219	CbGpPWpGaD
Vilazodone—HTR1A—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	0.000672	0.0021	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—SLC19A1—urinary bladder cancer	0.000665	0.00208	CbGpPWpGaD
Vilazodone—SLC6A4—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	0.000657	0.00206	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PRSS3—urinary bladder cancer	0.000648	0.00203	CbGpPWpGaD
Vilazodone—DRD2—Circadian rythm related genes—FAS—urinary bladder cancer	0.000628	0.00196	CbGpPWpGaD
Vilazodone—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000612	0.00192	CbGpPWpGaD
Vilazodone—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000604	0.00189	CbGpPWpGaD
Vilazodone—SLC6A4—Circadian rythm related genes—PTEN—urinary bladder cancer	0.000563	0.00176	CbGpPWpGaD
Vilazodone—DRD2—Circadian rythm related genes—CDK4—urinary bladder cancer	0.000552	0.00173	CbGpPWpGaD
Vilazodone—SLC6A4—Circadian rythm related genes—EP300—urinary bladder cancer	0.000537	0.00168	CbGpPWpGaD
Vilazodone—HTR1A—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	0.000534	0.00167	CbGpPWpGaD
Vilazodone—SLC6A4—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	0.000534	0.00167	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—TYMP—urinary bladder cancer	0.000518	0.00162	CbGpPWpGaD
Vilazodone—CYP2D6—Biological oxidations—GSTP1—urinary bladder cancer	0.000503	0.00158	CbGpPWpGaD
Vilazodone—DRD2—Circadian rythm related genes—PPARG—urinary bladder cancer	0.000502	0.00157	CbGpPWpGaD
Vilazodone—CYP2D6—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000497	0.00155	CbGpPWpGaD
Vilazodone—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	0.00049	0.00153	CbGpPWpGaD
Vilazodone—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	0.000475	0.00149	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—NAT2—urinary bladder cancer	0.000469	0.00147	CbGpPWpGaD
Vilazodone—CYP2D6—Biological oxidations—GSTM1—urinary bladder cancer	0.000463	0.00145	CbGpPWpGaD
Vilazodone—HTR1A—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	0.000458	0.00143	CbGpPWpGaD
Vilazodone—CYP2D6—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000456	0.00143	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—RRM2—urinary bladder cancer	0.000405	0.00127	CbGpPWpGaD
Vilazodone—HTR1A—G alpha (i) signalling events—CXCL8—urinary bladder cancer	0.000385	0.0012	CbGpPWpGaD
Vilazodone—SLC6A4—Circadian rythm related genes—TP53—urinary bladder cancer	0.000384	0.0012	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—ENO2—urinary bladder cancer	0.000375	0.00117	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—HPGDS—urinary bladder cancer	0.000375	0.00117	CbGpPWpGaD
Vilazodone—HTR1A—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	0.000372	0.00116	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—GSTT1—urinary bladder cancer	0.000364	0.00114	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—HDAC4—urinary bladder cancer	0.000345	0.00108	CbGpPWpGaD
Vilazodone—DRD2—Circadian rythm related genes—PTEN—urinary bladder cancer	0.000344	0.00108	CbGpPWpGaD
Vilazodone—DRD2—G alpha (i) signalling events—CXCL8—urinary bladder cancer	0.000338	0.00106	CbGpPWpGaD
Vilazodone—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	0.000329	0.00103	CbGpPWpGaD
Vilazodone—DRD2—Circadian rythm related genes—EP300—urinary bladder cancer	0.000328	0.00103	CbGpPWpGaD
Vilazodone—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000325	0.00102	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	0.000308	0.000965	CbGpPWpGaD
Vilazodone—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.000306	0.000957	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—HDAC4—urinary bladder cancer	0.000303	0.000948	CbGpPWpGaD
Vilazodone—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	0.000302	0.000946	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—NQO1—urinary bladder cancer	0.000302	0.000945	CbGpPWpGaD
Vilazodone—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000298	0.000933	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	0.000292	0.000915	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—NAT1—urinary bladder cancer	0.000292	0.000915	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—GLI1—urinary bladder cancer	0.000289	0.000905	CbGpPWpGaD
Vilazodone—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.000269	0.00084	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	0.000267	0.000837	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—GLI1—urinary bladder cancer	0.000254	0.000794	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—GSTP1—urinary bladder cancer	0.000252	0.000788	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	0.000241	0.000753	CbGpPWpGaD
Vilazodone—DRD2—Circadian rythm related genes—TP53—urinary bladder cancer	0.000235	0.000735	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—TYMS—urinary bladder cancer	0.000234	0.000733	CbGpPWpGaD
Vilazodone—HTR1A—GPCR ligand binding—CXCL8—urinary bladder cancer	0.000233	0.000729	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—GSTM1—urinary bladder cancer	0.000232	0.000724	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—NCOR1—urinary bladder cancer	0.000232	0.000724	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	0.000227	0.000711	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—GPX1—urinary bladder cancer	0.000222	0.000694	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	0.000222	0.000693	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—ERCC2—urinary bladder cancer	0.000218	0.000681	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—MTHFR—urinary bladder cancer	0.000205	0.00064	CbGpPWpGaD
Vilazodone—DRD2—GPCR ligand binding—CXCL8—urinary bladder cancer	0.000205	0.00064	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	0.000202	0.000631	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—RBX1—urinary bladder cancer	0.000198	0.00062	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	0.000191	0.000598	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—NAT1—urinary bladder cancer	0.000191	0.000598	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—TSC1—urinary bladder cancer	0.000186	0.000583	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—JAG1—urinary bladder cancer	0.000177	0.000555	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—TYMP—urinary bladder cancer	0.000177	0.000554	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	0.000175	0.000547	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—RBX1—urinary bladder cancer	0.000174	0.000544	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PPARG—urinary bladder cancer	0.000166	0.000519	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—TSC1—urinary bladder cancer	0.000164	0.000512	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—NAT2—urinary bladder cancer	0.00016	0.000501	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—CREBBP—urinary bladder cancer	0.000159	0.000499	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	0.000157	0.000493	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—JAG1—urinary bladder cancer	0.000156	0.000487	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—RHOA—urinary bladder cancer	0.00015	0.000469	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	0.000149	0.000465	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	0.000145	0.000453	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—S100B—urinary bladder cancer	0.000144	0.000449	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—RRM2—urinary bladder cancer	0.000138	0.000433	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—RHOA—urinary bladder cancer	0.000136	0.000426	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—RHOA—urinary bladder cancer	0.000132	0.000412	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—CXCL8—urinary bladder cancer	0.000132	0.000412	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PTGS2—urinary bladder cancer	0.000131	0.000408	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—NCOR1—urinary bladder cancer	0.000129	0.000404	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ENO2—urinary bladder cancer	0.000128	0.000401	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	0.000128	0.000401	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—S100B—urinary bladder cancer	0.000126	0.000395	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—IL2—urinary bladder cancer	0.000126	0.000394	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	0.000124	0.000389	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—RHOA—urinary bladder cancer	0.00012	0.000374	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—CXCL8—urinary bladder cancer	0.00012	0.000374	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—TYMP—urinary bladder cancer	0.000116	0.000362	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—CXCL8—urinary bladder cancer	0.000116	0.000362	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—IL2—urinary bladder cancer	0.000114	0.000357	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—TERT—urinary bladder cancer	0.000114	0.000356	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PTEN—urinary bladder cancer	0.000114	0.000356	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—NCOR1—urinary bladder cancer	0.000113	0.000355	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—IL2—urinary bladder cancer	0.00011	0.000346	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—EP300—urinary bladder cancer	0.000109	0.00034	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—CXCL8—urinary bladder cancer	0.000105	0.000328	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—NAT2—urinary bladder cancer	0.000105	0.000328	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—FGFR3—urinary bladder cancer	0.000104	0.000327	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—NQO1—urinary bladder cancer	0.000103	0.000323	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—ESR1—urinary bladder cancer	0.000101	0.000317	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—IL2—urinary bladder cancer	0.0001	0.000314	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—TERT—urinary bladder cancer	0.0001	0.000313	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—FGFR3—urinary bladder cancer	9.17e-05	0.000287	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—RRM2—urinary bladder cancer	9.04e-05	0.000283	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—ESR1—urinary bladder cancer	8.91e-05	0.000279	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CREBBP—urinary bladder cancer	8.89e-05	0.000278	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—IGF1—urinary bladder cancer	8.78e-05	0.000275	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—EGFR—urinary bladder cancer	8.74e-05	0.000273	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	8.61e-05	0.000269	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	8.37e-05	0.000262	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ENO2—urinary bladder cancer	8.37e-05	0.000262	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—KRAS—urinary bladder cancer	8.26e-05	0.000258	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	8.12e-05	0.000254	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—RHOA—urinary bladder cancer	8.05e-05	0.000252	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—TYMS—urinary bladder cancer	8e-05	0.00025	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	7.91e-05	0.000248	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	7.91e-05	0.000248	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CREBBP—urinary bladder cancer	7.81e-05	0.000244	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—IGF1—urinary bladder cancer	7.71e-05	0.000241	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—EGFR—urinary bladder cancer	7.67e-05	0.00024	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GPX1—urinary bladder cancer	7.58e-05	0.000237	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—ERBB2—urinary bladder cancer	7.45e-05	0.000233	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	7.44e-05	0.000233	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—KRAS—urinary bladder cancer	7.25e-05	0.000227	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—RHOA—urinary bladder cancer	7.06e-05	0.000221	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CXCL8—urinary bladder cancer	7.06e-05	0.000221	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—HRAS—urinary bladder cancer	7.02e-05	0.00022	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	6.99e-05	0.000219	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—IL2—urinary bladder cancer	6.75e-05	0.000211	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—NQO1—urinary bladder cancer	6.75e-05	0.000211	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CCND1—urinary bladder cancer	6.58e-05	0.000206	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—ERBB2—urinary bladder cancer	6.54e-05	0.000205	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—MMP9—urinary bladder cancer	6.39e-05	0.0002	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CDKN1A—urinary bladder cancer	6.37e-05	0.000199	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PTEN—urinary bladder cancer	6.35e-05	0.000199	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CXCL8—urinary bladder cancer	6.2e-05	0.000194	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—HRAS—urinary bladder cancer	6.16e-05	0.000193	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—EP300—urinary bladder cancer	6.06e-05	0.000189	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—IL2—urinary bladder cancer	5.93e-05	0.000185	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—SRC—urinary bladder cancer	5.89e-05	0.000184	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CCND1—urinary bladder cancer	5.78e-05	0.000181	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PPARG—urinary bladder cancer	5.67e-05	0.000177	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	5.63e-05	0.000176	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—MMP9—urinary bladder cancer	5.61e-05	0.000175	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CDKN1A—urinary bladder cancer	5.59e-05	0.000175	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PTEN—urinary bladder cancer	5.58e-05	0.000174	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	5.45e-05	0.00017	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—EP300—urinary bladder cancer	5.32e-05	0.000166	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—MYC—urinary bladder cancer	5.28e-05	0.000165	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—TYMS—urinary bladder cancer	5.23e-05	0.000164	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	5.17e-05	0.000162	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	5.17e-05	0.000162	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—SRC—urinary bladder cancer	5.17e-05	0.000162	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—EGFR—urinary bladder cancer	5.16e-05	0.000162	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GPX1—urinary bladder cancer	4.95e-05	0.000155	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—KRAS—urinary bladder cancer	4.88e-05	0.000153	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	4.86e-05	0.000152	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—MYC—urinary bladder cancer	4.63e-05	0.000145	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	4.57e-05	0.000143	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—EGFR—urinary bladder cancer	4.53e-05	0.000142	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	4.46e-05	0.00014	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—TP53—urinary bladder cancer	4.33e-05	0.000136	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—KRAS—urinary bladder cancer	4.28e-05	0.000134	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—HRAS—urinary bladder cancer	4.15e-05	0.00013	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PTEN—urinary bladder cancer	3.89e-05	0.000122	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—TP53—urinary bladder cancer	3.81e-05	0.000119	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—EP300—urinary bladder cancer	3.71e-05	0.000116	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PPARG—urinary bladder cancer	3.71e-05	0.000116	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—HRAS—urinary bladder cancer	3.64e-05	0.000114	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	3.56e-05	0.000111	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	2.92e-05	9.12e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PTEN—urinary bladder cancer	2.54e-05	7.96e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—EP300—urinary bladder cancer	2.43e-05	7.59e-05	CbGpPWpGaD
